Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders

Jensen, Morten Krogh; Brown, Peter de Nully; Lund, B; Nielsen, Ove Juul; Hasselbalch, Hans Carl

doi:10.1046/j.1365-2141.2000.02030.x

Cited by 110 publications

(107 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A propensity for thrombosis might be explained by an increased haematocrit level in polycythaemia vera and an inherent platelet activation as evidenced by abnormal eicosanoid metabolism, serological measurements of a-granule products, and spontaneous platelet aggregation [7À10]. In line with this, using whole blood¯ow cytometry we have recently demonstrated an increased platelet membrane expression of the a-granule proteins P-selectin and thrombospondin (TSP) in nonstimulated platelets of patients with MPD indicating increased granule secretion [11]. In addition, the expression of P-selectin and TSP positive platelets was positively correlated to the presence of plateletÀle-ukocyte aggregates [12].…”

Section: Introductionmentioning

confidence: 79%

“…In the present study, we have evaluated the presence of risk markers for venous thromboembolism, ®brinolytic, and haemostatic system activation markers and antiphospholipid antibodies in a cohort of 50 patients with MPD and ascertained whether any marker of hypercoagulation or ®brinolysis was linked to the presence of activated platelets and plateletÀgranulocyte/monocyte aggregates [11,12]. Previous studies have indicated that in MPD activation of the coagulation system might be present as evidenced by elevations in prothrombin fragment 1+2 and ®-brinopeptide A levels [24À26].…”

Section: Discussionmentioning

confidence: 99%

“…Characteristics of the patient cohort and control subjects have been described in two previous reports [11,12]. Fifty patients with MPD and 30 controls were enrolled in the study after giving written informed consent.…”

Section: Materials and Methods Patients And Normal Control Subjectsmentioning

confidence: 99%

“…Flow cytometric analyses of plateletÀgranulocyte/ monocyte aggregates and platelet activation markers in this cohort of patients and controls have been described in detail previously [11,12].…”

Section: Assay Proceduresmentioning

confidence: 99%

“…The aim of the present study was to investigate a previously reported cohort of patients with MPD [11,12] with respect to (i) Factor V Leiden and prothrombin G20210A mutations and other risk markers for venous thromboembolism, (ii) ®brinolytic and haemostatic system activation markers, and (iii) antiphospholipid antibodies. It was also the aim to ascertain whether platelet activation and plateletgranulocyte/monocyte aggregates could provide a link to disturbances of the coagulation system.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders

et al. 2002

Self Cite

View full text Add to dashboard Cite

Chronic myeloproliferative disorders (MPD) are characterized by a high incidence of thrombohaemorrhagic complications, possibly related to platelet abnormalities and disturbances of the coagulation system. In an attempt to de®ne abnormalities in coagulation and ®brinolysis, we investigated risk markers for venous thromboembolism, ®-brinolytic, and haemostatic system activation markers and antiphospholipid antibodies in blood samples from 50 MPD patients and 30 controls. Compared with controls median levels of protein S free and protein C were signi®cantly decreased in the patients (0.27 vs. 0.38 arbitrary units; P < 0.001 and 0.86 vs. 0.99 arbitrary units; P < 0.001, respectively), and activated partial thromboplastin time was signi®cantly prolonged in patients (33 vs. 27 sec; P < 0.001). No dierences were observed in levels of antithrombin, thrombin± antithrombin complex, and ®brin D-dimer. In patients the median value of thrombomodulin was signi®cantly increased indicating perturbed endothelial function. Anticardiolipin antibodies of IgM subtype (median 38 U/mL, 33±99) were detected in 11 patients (22%) and only in one control (3%) (P < 0.021; patients vs. controls). Seven patients were heterozygous for the Factor V Leiden, one patient was heterozygous for the prothrombin G20210A mutation, and one patient was homozygous for the Factor V Leiden mutation. Among controls, two were heterozygous for the Factor V Leiden mutation. Comparing the allele frequency of the Factor V Leiden mutation in patients with MPD and the background population disclosed a signi®cantly increased allele prevalence of the Factor V Leiden mutation in the patients (9% vs. 3.4%; P = 0.003). Alterations in the level of anticoagulant proteins, disturbances of endothelial cell function, and the presence of cardiolipin antibodies and Factor V Leiden mutation may increase the cumulative thrombotic risk in MPD besides the risk imposed by platelet activation. Am.

show abstract

Section: Introductionmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Section: Materials and Methods Patients And Normal Control Subjectsmentioning

confidence: 99%

Section: Assay Proceduresmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations